IntraRenal HEmoDynamics to IntegraTE CA-AKI Risk and Monitor NephroprotectiIoN by ImpElla Support.

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Sep 12, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to identify patients at risk for a specific type of kidney damage called contrast-associated acute kidney injury (CA-AKI), which can happen after certain heart procedures. Researchers believe that measuring something called the intrarenal resistive index (RI) can help predict who is at a higher risk for this issue. The trial also investigates whether using a device called Impella can help protect the kidneys during these procedures by improving blood flow within the kidneys.

To participate in this trial, patients need to be between 18 and 90 years old and scheduled for a heart procedure known as PCI within the next week. However, certain conditions, such as severe kidney disease or recent heart attacks, may prevent someone from joining. Participants will undergo specific tests and monitoring during the trial, and they can expect to receive support and follow-up care related to their kidney health. This study is currently recruiting participants, and it aims to improve the understanding and prevention of kidney injury in patients with heart issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must meet all of the Inclusion Criteria to participate in the trial.
• • 1. Age ≥18 years and \<90 years
• • 2. Scheduled for PCI or PROTECTED PCI in near future (1 week) or PCI same day.
• Exclusion Criteria:
• • Subjects must NOT meet any of the following Exclusion Criteria to participate in the trial.
• • 1. Severe chronic kidney disease with eGFR ≤ 20 ml/min or on dialysis
• • 2. Patients with AKI within the last seven days prior screening or incipient AKI (in cases, where AKI cannot be ruled out as a cause for elevated serum creatinine, a rise or fall above 30% of a second serum creatinine measurement obtained within 12 to 24 hours is regarded indicative of AKI).
• • 3. STEMI ≤24 hours from the onset of ischemic symptoms or at any time if mechanical complications of transmural infarction are present (e.g., VSD, papillary muscle rupture, etc.)
• • 4. Cardiogenic shock (SBP \<80 mmHg for ≥30 mins and not responsive to intravenous fluids or hemodynamic deterioration for any duration requiring pressors or mechanical circulatory support, including IABP)
• • 5. Cardiorespiratory arrest related to the current admission unless subject is extubated for \>24 hours with full neurologic recovery and hemodynamically stable.
• • 6. Platelet count \<75,000 cells/mm3, bleeding diathesis or active bleeding, coagulopathy or unwilling to receive blood transfusions.
• • 7. Pregnant or child-bearing potential unless negative pregnancy test within 1 week
• • 8. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint
• • 9. Any medical or psychiatric condition such as dementia, alcoholism or substance abuse which may preclude informed consent or interfere with any of the study procedures, including follow-up visits
• • 10. Any non-cardiac condition with life expectancy \<1 years (e.g., cirrhosis, cancer not in remission, etc.)
• • 11. Subject belongs to a vulnerable population (defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention)